Black Diamond Therapeutics (BDTX) Investor Presentation - Slideshow

Pipeline and Programs - Black Diamond Therapeutics is developing MasterKey therapies targeting oncogene mutation families to provide precision oncology medicines for genetically defined tumors[7] - BDTX-1535, a brain-penetrant, mutant-selective, irreversible EGFR inhibitor, is in Phase 1 clinical trials for GBM and NSCLC patients with EGFR intrinsic & acquired resistance mutations[7] - BDTX-4933, a brain-penetrant inhibitor of Class I, II, and III oncogenic BRAF mutations, is in IND-enabling studies with an expected IND filing in the first half of 2023[7, 11] - The company anticipates nominating a development candidate for its FGFR2/3 program in 2022 and for an undisclosed target program in 2023[11] Technology and Approach - Black Diamond's MAP drug discovery engine is designed to predict and validate novel oncogenic mutant families, pioneer mutant family conformation-based MasterKey drug design, and provide opportunities beyond oncology and small molecules[7] - The MasterKey approach targets mutation families to expand the opportunity for precision oncology, addressing populations lacking suitable precision therapies; less than 15% of patients with metastatic cancer are eligible for approved precision oncology medicines[10] - BDTX-1535 is designed for potent & selective inhibition across mutant families, with average IC50 of 3.8 nM against intrinsic resistance mutations and 3.5 nM against classical & acquired resistance mutations in NSCLC[25, 26] Financials and Milestones - As of December 31, 2021, Black Diamond Therapeutics had $209 million in cash, cash equivalents, and investments, providing a cash runway into the third quarter of 2024[59]